Pharmacogenomics in practice: a review and implementation guide
Frontiers in Pharmacology · 18.05.2023 · 14
DOI: 10.3389/fphar.2023.1189976 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.05.2023. Verfasst von Danya Kabbani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erasmus+.
Abstract (Originalsprache)
Considerable efforts have been exerted to implement Pharmacogenomics (PGx), the study of interindividual variations in DNA sequence related to drug response, into routine clinical practice. In this article, we first briefly describe PGx and its role in improving treatment outcomes. We then propose an approach to initiate clinical PGx in the hospital setting. One should first evaluate the available PGx evidence, review the most relevant drugs, and narrow down to the most actionable drug-gene pairs and related variant alleles. This is done based on data curated and evaluated by experts such as the pharmacogenomics knowledge implementation (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC), as well as drug regulatory authorities such as the US Food and Drug Administration (FDA) and European Medicinal Agency (EMA). The next step is to differentiate reactive point of care from preemptive testing and decide on the genotyping strategy being a candidate or panel testing, each of which has its pros and cons, then work out the best way to interpret and report PGx test results with the option of integration into electronic health records and clinical decision support systems. After test authorization or testing requirements by the government or drug regulators, putting the plan into action involves several stakeholders, with the hospital leadership supporting the process and communicating with payers, the pharmacy and therapeutics committee leading the process in collaboration with the hospital laboratory and information technology department, and healthcare providers (HCPs) ordering the test, understanding the results, making the appropriate therapeutic decisions, and explaining them to the patient. We conclude by recommending some strategies to further advance the implementation of PGx in practice, such as the need to educate HCPs and patients, and to push for more tests’ reimbursement. We also guide the reader to available PGx resources and examples of PGx implementation programs and initiatives.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
- Department of Pharmaceutical Biochemistry, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
Förderung
- Erasmus+
Zitieren
APA
Kabbani, D., Akika, R., Wahid, A., Daly, A. K., Cascorbi, I., & Zgheib, N. K. (2023). Pharmacogenomics in practice: a review and implementation guide. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1189976
Vancouver
Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I, Zgheib NK. Pharmacogenomics in practice: a review and implementation guide. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1189976
BibTeX
@article{Kabbani2023,
author = {Kabbani, Danya and Akika, Reem and Wahid, Ahmed and Daly, Ann K and Cascorbi, Ingolf and Zgheib, Nathalie Khoueiry},
title = {Pharmacogenomics in practice: a review and implementation guide},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1189976}
}
EUVIMED